Klivira
Request demo

Streamlining Aetna Trulicity Prior Authorization Workflows

Navigating the Aetna Trulicity prior authorization process can be complex, involving multiple submission channels and stringent clinical criteria. Klivira automates these workflows to improve efficiency and reduce administrative burden.

For revenue cycle directors and prior authorization coordinators, managing high-volume drug authorizations like Trulicity (dulaglutide) with a large national payer like Aetna demands precision. Understanding Aetna's specific requirements, submission pathways, and utilization management policies is critical to ensuring timely patient access to this GLP-1 agonist for type 2 diabetes.

Understanding Aetna's Coverage for Trulicity (dulaglutide)

Trulicity (dulaglutide), a GLP-1 agonist indicated for type 2 diabetes, typically falls under the pharmacy benefit for Aetna members. As such, prior authorization requests are administered through CVS Caremark, Aetna's Pharmacy Benefit Manager (PBM). Common prior authorization requirements include step therapy, often requiring documentation of prior trials with oral antidiabetic agents.

Aetna Prior Authorization Submission Channels for Trulicity

For pharmacy-benefit medications like Trulicity, Aetna leverages its PBM, CVS Caremark, for prior authorization processing. Retail pharmacy prior authorizations are primarily routed through established ePA partners such as CoverMyMeds and Surescripts. For mail-order prescriptions or specific case-managed scenarios, direct submission via CVS Caremark's provider portal may be required. While Aetna supports X12 278 transactions and the Availity portal for medical benefit precertification, these are not typically the primary channels for pharmacy-benefit drugs like Trulicity.

Navigating Aetna's Utilization Management Policies for GLP-1 Agonists

Aetna's medical necessity criteria for Trulicity are published within their Clinical Policy Bulletins (CPBs). These CPBs are versioned, dated, and serve as the canonical source for specific clinical requirements, including step therapy protocols and indications. Prior authorization coordinators must reference the applicable CPB number and review date to ensure submissions align with Aetna's current guidelines for GLP-1 agonists.

Common Denial Reasons and Appeal Pathways for Trulicity with Aetna

Denials for Trulicity prior authorizations with Aetna often stem from insufficient documentation of medical necessity, failure to meet step therapy requirements, or incomplete clinical information. Denial reasons are typically communicated via X12 835/277 transactions or through portal status updates, utilizing CARC and RARC vocabularies. The appeal pathway generally includes reconsideration, peer-to-peer review, and formal appeal processes, with expedited options available for urgent cases. Timely-filing windows and specific appeal levels are detailed in Aetna's provider manuals and vary by line of business and state regulations.

Klivira's Role in Automating Aetna Trulicity Prior Authorizations

Klivira integrates directly with EMR systems and payer portals to automate the end-to-end Aetna Trulicity prior authorization workflow. By leveraging ePA capabilities through partners like CoverMyMeds and Surescripts, and streamlining data submission to CVS Caremark, Klivira reduces manual effort and improves accuracy. Our platform helps ensure that all necessary clinical documentation is gathered and submitted in accordance with Aetna's specific Clinical Policy Bulletins, minimizing delays and denials for dulaglutide.

Frequently asked questions

What are the common Aetna prior authorization requirements for Trulicity?

Aetna's prior authorization for Trulicity (dulaglutide) commonly requires documentation of medical necessity for type 2 diabetes and adherence to step therapy protocols. This often means demonstrating a trial and failure or contraindication to less-expensive oral antidiabetic agents. Specific criteria are detailed in Aetna's Clinical Policy Bulletins (CPBs).

How do I submit an electronic prior authorization (ePA) for Trulicity to Aetna?

For pharmacy-benefit drugs like Trulicity, electronic prior authorization (ePA) requests to Aetna are typically submitted through ePA platforms such as CoverMyMeds or Surescripts. These platforms facilitate the digital exchange of clinical information required by Aetna's PBM, CVS Caremark, for review.

Where can I find Aetna's clinical criteria for Trulicity?

Aetna's specific clinical criteria and utilization management policies for Trulicity (dulaglutide) are published in their public Clinical Policy Bulletins (CPBs). These CPBs are accessible through Aetna's provider resources and should be referenced by their canonical CPB number and effective date to ensure compliance with current guidelines.

What is the appeal process for a denied Trulicity prior authorization with Aetna?

If a Trulicity prior authorization is denied by Aetna, the appeal process typically begins with a reconsideration request, followed by options for peer-to-peer review, and formal appeals. Expedited appeal pathways are available for urgent situations. Details regarding timely-filing limits and required documentation for each appeal level are outlined in Aetna's provider manuals.

Does Aetna's Da Vinci PAS initiative impact Trulicity prior authorizations?

Aetna participates in HL7 connectathons related to Da Vinci PAS and other electronic prior authorization standards like CRD and DTR. While these initiatives aim to streamline prior authorizations, the current production conformance for specific drugs like Trulicity under the Da Vinci PAS IG requires independent verification. Klivira focuses on leveraging existing ePA partnerships to ensure immediate operational efficiency.

Related coverage

Other trulicity prior authorization by payer

Other trulicity prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo